Biomaterials · 2026
A hybrid nanoadjuvant cascading activation of the cGAS-STING-IFN-Ⅰ pathway to enhance radio-immunotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Zhaohui, Zhang Peng, Cui Guangzu, Liu Yongting, Wang Xinwen, Zhou Zaigang, Fei Jiang, Wang Kailing, Li Yin, Zhang Xiangyang, Shen Hong, Zeng Shan, Han Ying, Shen Jianliang
Аннотация
The cGAS-STING signaling pathway is crucial for radiotherapy (RT)-induced immune modulation. However, under hypoxic conditions, reduced DNA damage and enhanced DNA damage repair (DDR) lead to lower cytosolic double-stranded DNA (dsDNA) levels, making standard RT doses inadequate for sustained cGAS-STING activation, resulting in transient immune responses. In this study, we developed the As-Mn@MnO2@Alb nanosystem as a potent radiosensitizer and cGAS-STING pathway amplifier. Arsenic trioxide (ATO)-mediated radiosensitization suppresses DDR, enhances immunogenic cell death, and increases tumor-associated antigens and cytosolic dsDNA levels. Concurrently, degradable MnO2 releases Mn2+ in tumors, boosting cGAS recognition and sensitivity, while generating oxygen to alleviate hypoxia and improve RT efficacy. The synchronized delivery of Mn2+ and accumulated cytosolic dsDNA amplifies cGAS-STING activation, promoting dendritic cell (DC) maturation, enhancing CD8+ T cell infiltration, reducing immunosuppressive Treg infiltration, and significantly inhibiting both irradiated local tumors and non-irradiated distal CRC tumors while inducing robust immune memory effects, all with no notable toxicity. This study demonstrates that effective RT sensitization, coupled with synchronized STING activation, represents a robust strategy to overcome radio-immunotherapy resistance in colorectal cancer.